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Edited by Peter Tontonoz and Laszlo NagyAbstract Non-alcoholic fatty liver disease is tightly associated
with insulin resistance, type 2 diabetes and obesity, but the
molecular links between hepatic fat accumulation and insulin
resistance are not fully identiﬁed. Excessive accumulation of tri-
glycerides (TG) is one the main characteristics of non-alcoholic
fatty liver disease and fatty acids utilized for the synthesis of
TG in liver are available from the plasma non-esteriﬁed fatty
acid pool but also from fatty acids newly synthesized through
hepatic de novo lipogenesis. Recently, the transcription factor
ChREBP (carbohydrate responsive element binding protein)
has emerged as a central determinant of lipid synthesis in liver
through its transcriptional control of key genes of the lipogenic
pathway, including fatty acid synthase and acetyl CoA carboxyl-
ase. In this mini-review, we will focus on the importance of
ChREBP in the physiopathology of hepatic steatosis and insulin
resistance by discussing the physiological and metabolic conse-
quences of ChREBP knockdown in liver of ob/ob mice.
 2007 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Non-alcoholic liver disease (NAFLD) is emerging as the
most common chronic liver disease in the Western countries.
NAFLD, which describes a large spectrum of liver histopa-
thological features including simple steatosis, non-alcoholic
steatohepatitis (NASH), cirrhosis and hepatocellular carci-
noma [1] is associated in the vast majority of the cases, with
obesity, insulin resistance and type 2 diabetes. Excessive accu-
mulation of triglycerides (TG) is the one main characteristics
of hepatic steatosis, a pathological pattern that is now consid-
ered as a component of the metabolic syndrome [2]. Fatty
acids utilized for the synthesis of TG in liver are available from
the plasma non-esteriﬁed fatty acid pool (NEFA) but also
from fatty acids newly synthesized through hepatic de novo
lipogenesis. Triglycerides can then be stored as lipid droplets
within the hepatocytes or secreted into the blood as VLDL*Corresponding author. Address: Institut Cochin, Universite´ Paris
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doi:10.1016/j.febslet.2007.07.084but they can also be hydrolyzed and the fatty acids channelled
towards the b-oxidation. Although the mechanisms involved in
the pathogenesis of NAFLD have not been thoroughly inves-
tigated in humans, both increased de novo fatty acid synthesis
and decreased b-oxidation in the mitochondria have been
implicated in the development of the pathology [3,4].
De novo lipogenesis is nutritionally regulated and both glu-
cose and insulin signaling pathways are elicited in response to
dietary carbohydrates to synergistically induce glycolytic and
lipogenic gene expression. The transcription factor SREBP-
1c (sterol regulatory element binding protein-1c) has previ-
ously emerged as a major mediator of insulin action on lipo-
genic genes, such as acetyl CoA carboxylase (ACC) and fatty
acid synthase (FAS) [5] (Fig. 1). However, SREBP-1c activity
alone is not suﬃcient to account for the stimulation of glyco-
lytic and lipogenic gene expression in response to carbohydrate
since SREBP-1c gene deletion in mice only results in a 50%
reduction in fatty acid synthesis [6]. More importantly, L-pyru-
vate kinase (L-PK), one of the rate-limiting enzyme of glycol-
ysis is exclusively dependant on glucose [7] and is not subjected
to SREBP-1c regulation [8]. Until recently, the nature of the
glucose-signaling compound was not known, but the recent
identiﬁcation of a glucose-responsive basic/helix–loop–helix/
leucine zipper (bHLH/LZ) transcription factor named ChRE-
BP (carbohydrate responsive element binding protein) has
shed light on the mechanism whereby glucose aﬀects gene tran-
scription [9,10]. ChREBP is a large protein (864 amino acids
and Mr = 94600) that contains several domains including a
nuclear localization signal (NLS) near the N-terminus, poly-
proline domains, a basic loop–helix–leucine-zipper (b/HLH/
Zip) and a leucine-zipper-like (Zip-like) domain. Glucose acti-
vates ChREBP by regulating its entry from the cytosol into the
nucleus [11,12] thereby promoting its binding to carbohydrate
responsive element (ChoRE) present in the promoter regions
of glycolytic and lipogenic genes [13]. Studies by the Towle lab-
oratory have revealed that ChREBP binds as a heterotetramer,
together with its functional partner Mlx (Max like protein) on
ChoRE elements [14,15].
ChREBP is also regulated by glucose at the transcriptional
level [16]. Interestingly, ChREBP was also recently identiﬁed
as a direct target of liver X receptors (LXRs) [17] (Fig. 1). LXRs
are ligand-activated transcription factors that belong to the
nuclear hormone receptor superfamily [18]. LXRs play a cen-
tral role in cholesterol and bile acid metabolisms [19] but are
also important regulators of the lipogenic pathway [20] through
the transcriptional control of SREBP-1c [21], FAS [22]
ACC [23] and stearoyl-CoA desaturase 1 (SCD-1) [24], theation of European Biochemical Societies.
Fig. 1. Transcriptional control of glycolysis and lipogenesis. The
conversion of glucose into fatty acids through de novo lipogenesis is
nutritionally regulated and both glucose and insulin signaling path-
ways are elicited in response to dietary carbohydrates to synergistically
induce glycolytic and lipogenic gene expression. The transcription
factor SREBP-1c (Sterol Regulatory Element binding Protein) has
emerged as a major mediator of insulin action on lipogenic genes, such
as fatty acid synthase (FAS) and acetyl CoA carboxylase (ACC) [5].
The nature of the glucose-signaling compound was recently identiﬁed
as being ChREBP (carbohydrate responsive element binding protein).
Glucose activates ChREBP by stimulating its gene expression and by
regulating its entry from the cytosol into the nucleus thereby
promoting its binding to carbohydrate responsive element (ChoRE)
present in the promoter regions of its target genes [10]. ChREBP is
required for the induction of L-pyruvate kinase (L-PK), which is
exclusively dependant on glucose. Induction of FAS and ACC genes is
under the combined action of ChREBP and of SREBP-1c in response
to glucose and insulin, respectively. ChREBP is also a direct target of
LXRs (Liver X receptors) [17], nuclear receptors implicated in the
lipogenic pathway, through the direct transcriptional activation of
ACC and FAS but also indirectly via SREBP-1c. Indeed, LXRs are
central for the insulin-mediated activation of SREBP1-c. Recently, the
observation that glucose binds and activates nuclear LXRs placed
LXRs at the center masters of the glucose-signaling pathway [27].
Whether LXRS are implicated in the glucose-induction of ChREBP
and other glucose-regulated genes needs to be addressed in a
physiological context.
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palmitoleate and oleate from saturated fatty acids [25]. In fact,
LXRs are central for the insulin-meditated induction of
SREBP-1c [21,26] (Fig. 1). Known ligands of LXRs are oxys-
terols but, interestingly, glucose was also recently shown to
activate LXRs and to induce their target genes, including
ChREBP (Fig. 1) [27]. This study directly implicated LXRs
as master regulators of the glucose-signaling pathway and chal-
lenged the role of previously recognized glucose-sensors such as
glucokinase (GK), the ﬁrst enzyme of the glycolytic pathway.
Indeed, we have previously shown that hepatic GK is acting
as a glucose-sensor in liver and is required for the expression
of ChREBP as well as the subsequent induction of glycolytic
and lipogenic genes. However, as raised by Wilson and Lazar
[28] several concerns aroused from the study of Mitro et al.
[27] including the fact that both D-glucose and L-glucose (which
is inactive in most biological reaction including GK activity)
were found to activate LXRs [29] and that the experiments were
performed in HepG2 cells, an hepatoma cell line that respond
poorly to glucose. Clearly, studies performed in a physiological
context will be necessary to help understand the physiological
relevance of LXRs as glucose-sensors in liver (Fig. 1).
In contrast, the role of ChREBP as a central mediator of the
eﬀect of glucose on glycolytic and lipogenic genes is now
clearly established. ChREBP is required for the induction ofL-PK [11,16] and acts in synergy with SREBP-1c to induce
FAS and ACC to glucose and insulin, respectively [30]
(Fig. 1). Furthermore, ChREBP silencing in hepatocytes [16]
and in mice [31] not only leads to the lack of induction of L-
PK, FAS and ACC genes in response to glucose but also
causes a signiﬁcant reduction in lipid synthesis. This mini-
review will focus on the recent emergence of ChREBP in the
control of the lipogenic pathway and address its role in the
physiopathology of hepatic steatosis and insulin resistance in
the ob/ob mouse model.2. Use of the genetically obese ob/ob mice for the study of
hepatic steatosis and insulin resistance
We chose to elucidate the implication of ChREBP in the
physiopathology of hepatic steatosis in ob/ob mice. Indeed,
ob/ob mice have been extensively studied and represent a nat-
urally occurring model of NAFLD. These mice are leptin-deﬁ-
cient due to a mutation in the ob gene, which encodes leptin
and therefore prevents its synthesis [32]. Leptin, a satiety hor-
mone synthesized by the white adipose tissue, inhibits feeding
behavior and increases energy expenditure by acting on
anorexigenic neurons in the ventral median nucleus of the
hypothalamus [33]. In the absence of leptin, ob/ob mice are
hyperphagic, inactive and become obese. These mice are also
insulin resistant and hyperinsulinemic, with resultant hyper-
glycemia and hyperlipidemia. Most importantly, ob/ob mice
develop spontaneously fatty livers due, in part to an exacer-
bated glycolytic and lipogenic pathway [34]. The up-regulation
of the lipogenic pathway in liver is rather puzzling since ob/ob
mice are insulin-resistant as evidenced by the decreased in the
insulin-mediated phosphorylation of key eﬀectors of the sig-
naling pathway, including insulin susbrate 1 (IRS-1) and phos-
phatidyl-inositol-3-kinase (PI3K) [35,36]. However, despite a
clear state of hepatic insulin resistance, the expression of key
genes of the lipogenic pathway, including FAS and SREBP-
1c is markedly elevated in livers of ob/ob mice [37]. The mech-
anisms involved in this up-regulation are not clear especially
considering that genes of the gluconeogenic pathway (phos-
phoenol pyruvate carboxykinase (PEPCK) and glucose 6
phosphatase (G6Pase)), inhibited by insulin under normal con-
ditions, are up-regulated in liver ob/ob mice, in agreement with
their state of insulin resistance [38]. The sustained expression
of PEPCK and G6Pase causes an enhanced hepatic glucose
production and resultant hyperglycemia in ob/ob mice.
We ﬁrst established a potential molecular link between
ChREBP and hepatic steatosis in ob/ob mice by determining
that ChREBP gene expression and nuclear protein content
were markedly increased in livers of these mice under both
fasted and fed conditions [39]. Under fed conditions, we ob-
served a concomitant increase in nuclear ChREBP and
SREBP-1c content supporting the fact that these two tran-
scription factors contribute to the high rates of lipogenesis that
leads to hepatic steatosis in ob/ob mice. However, under fasted
conditions, only ChREBP content was increased compared to
ob/+ controls suggesting that ChREBP by itself may be
responsible for the increased rates of lipogenesis measured
after a 24 h fast in ob/ob mice [39] (Fig. 2). Interestingly, a re-
cent study reports that increased metabolism via GK, the ﬁrst
and rate-limiting enzyme of the glycolytic pathway is suﬃcient
to induce lipogenic gene expression in liver of streptozotocin-
Fig. 2. Correlation between ChREBP nuclear levels and lipogenic
rates in liver. Under both fasted and 18 h high-carbohydrate-fed
(HCHO) conditions, a strong correlation was observed between
ChREBP nuclear protein content and the high rates of lipogenesis in
liver of both ob/+ and ob/ob mice supporting the hypothesis that
ChREBP contributes to the development of hepatic steatosis in ob/ob
mice. Adapted from Dentin et al. [39].
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[40]. In fact, in this rat model, the over-expression of GK re-
stores the expression of ChREBP and rescues lipogenic gene
expression. It should be noted however that this study only re-
ported ChREBP and SREBP-1c expression at mRNA levels
when it is well known that these two transcription factors
are also submitted to important post-traductional regulations
[10,41]. Clearly, the respective roles of ChREBP andFig. 3. The metabolic parameters of the ob/ob are improved after ChREBP kn
successful after 7 days in decreasing hepatic fat accumulation in liver of
triglyceride (TG) and free fatty acid (FFA) concentrations. The beneﬁcial eﬀ
tolerance and insulin sensitivity with a signiﬁcant improvement in both hypSREBP-1c in controlling the lipogenic pathway needs to be
determined. While the mechanism by which ChREBP expres-
sion is increased in liver of ob/ob mice is unknown it could
be directly caused by chronic exposure to hyperglycemia since
glucose metabolism through hepatic GK is required for the
induction of ChREBP in liver [16,40]. The fact that both GK
expression and glucose metabolism are elevated in liver of
ob/ob mice supports this hypothesis. Another point that should
be taken in consideration concerning the elevated expression of
ChREBP in liver of ob/ob mice is that these mice being leptin-
deﬁcient. Since leptin has been shown to decrease SREBP-1c
expression in various mouse models including, leptin-treated
ob/ob mice, IRS-2 knockout mice and in lipoatrophic mice
[42,43] it would be interesting to determine whether leptin
treatment in ob/ob mice is able to signiﬁcantly decrease ChRE-
BP expression in liver.3. Liver-speciﬁc inhibition of ChREBP in liver of ob/ob mice
To determine if beneﬁcial eﬀects could result from reduced
hepatic expression of ChREBP, adenoviral-based short-hair-
pin (shRNA) technology was used to knockdown ChREBP
expression in livers of ob/ob mice. Adenoviral delivery of
shRNA in vivo has been proven to be successful for studying
the eﬀects of knocking down genes involved in liver metabo-
lism [44–46] without the potential compensatory eﬀects ob-
served in gene knockout mice. Under both short (2 days)
and long term (7 days) conditions, ChREBP was eﬃciently de-
creased after shRNA treatment. A resultant decrease in lipo-
genic rates was observed thereby signiﬁcantly decreasing
hepatic fat accumulation in liver as well as free fatty acid con-
centrations [39] (Fig. 3). In agreement with our previous
in vitro studies [16], inhibition of ChREBP markedly aﬀectedockdown in liver. Adenoviral delivery of shRNA against ChREBP was
ob/ob mice as well as decreasing plasma lipid parameters including
ect of ChREBP knockdown was therefore apparent on overall glucose
erglycemia and hyperinsulinemia. Adapted from Dentin et al. [39].
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but also reduced the expression of SCD-1 as well as glyceralde-
hyde 3-phosphate acyltransferase (GPAT), the enzyme that
controls the ﬁrst step of triglyceride synthesis. Both SCD1
[47] and GPAT [46] have been previously linked to hepatic ste-
atosis in ob/ob mice. Therefore, ChREBP by transcriptionnally
controlling most of the lipogenic program (ACC, FAS, SCD-
1), TG synthesis at the level of GPAT and potentially VLDL
export (R. Dentin and C. Postic, unpublished observations)
appears as a central modulator of fatty acid concentrations
in liver. Altogether our results suggest a broader transcrip-
tional role for ChREBP and micro-RNA analysis could help
identify potential novel targets.
Hepatic insulin resistance has been associated with steatosis
in both rodents [48] and humans [49]. This resistance could re-
sult from the contribution of adipose tissue through increased
ﬂux of free fatty acids (FFA) to the liver or by secretion of
numerous adipocytokines, which may aﬀect hepatic insulin
action. Although the association between hepatic insulin
resistance and TG accumulation in liver is clear, the causative
role for hepatic insulin resistance in the accumulation of TG
has not clearly established. Nevertheless, by markedly prevent-
ing TG accumulation in liver of ob/ob mice, ChREBP knock-
down signiﬁcantly restored insulin sensitivity in liver as
evidenced by the restoration of protein kinase B (Akt), and
Foxo1 phosphorylation by insulin [39]. The transcription fac-
tor Foxo1 plays a pivotal role in the control of gluconeogenesis
by transcriptionnally regulating the expression of PEPCK and
G6Pase in liver [50–52]. Insulin-mediated Akt phosphorylation
of Foxo1 leads to its nuclear exclusion, ubiquitination and
degradation [53]. The subsequent decrease in nuclear Foxo1Fig. 4. Summary of ChREBP knockdown in liver. Consequently to adenori
and triglyceride (TG) synthesis are decreased. As a result, the restored inhibit
insulin leads to the improvement of blood glucose levels. Correction of he
esteriﬁed fatty acids (NEFA). As a consequence, insulin sensitivity is resto
contributing to the decrease in blood glucose concentrations observed. Th
hyperinsulinemia and hyperlipidemia. Adapted from Dentin et al. [39].decreases expression levels of PEPCK and G6Pase, thereby
decreasing gluconeogenic rates and reducing blood glucose.
In agreement with these studies, ChREBP knockdown, by res-
cuing Foxo1 phosphorylation by insulin, led to an eﬃcient
inhibition of PEPCK and G6Pase, associated with a subse-
quent normalization of blood glucose levels in shChREBP
RNA treated-ob/ob mice [39] (Fig. 4).
Interestingly, insulin sensitivity was not only restored in liver
but also in skeletal muscles and adipose tissue, in which we
also observed a signiﬁcant improvement in Akt phosphoryla-
tion in response to the insulin bolus [39]. As a result, glycogen
content was restored to control levels in skeletal muscles from
shChREBP RNA treated-ob/ob mice. It is important to note
that ChREBP knockdown was only targeted to liver of ob/ob
mice and that the metabolic improvements observed on both
skeletal muscle and adipose tissue were indirect, probably
due to the fact that hyperlipidemia (FFA and plasma TG con-
centrations) were markedly reduced in these mice [39]. The
beneﬁcial eﬀect of ChREBP knockdown was therefore appar-
ent on overall glucose tolerance and insulin sensitivity with a
signiﬁcant improvement in hyperlipidemia, hyperglycemia,
and hyperinsulinemia (Fig. 3). Altogether, our results show
that modulating the expression of a single gene in liver of ob/
ob mice signiﬁcantly lowered circulating lipid and blood glu-
cose concentrations inducing a beneﬁcial interaction between
liver, skeletal muscle and adipose tissue. Liver plays a key role
in the control of energy balance [54] and aﬀecting gene expres-
sion in liver was previously demonstrated to lead to extra-
hepatic consequences. For example, enhancing glycolysis at
the level of GK in a mouse model of obesity causes a signiﬁ-
cant increase in energy expenditure in skeletal muscle, throughvus-mediated inhibition of ChREBP in liver of ob/ob mice, lipogenesis
ion of genes from the gluconeogenic pathway (G6Pase and PEPCK) by
patic steatosis also leads to decreased levels of plasma TG and non-
red in skeletal muscles and glycogen synthesis is enhanced, therefore
e overall phenotype is a signiﬁcant improvement in hyperglycemia,
72 P.-D. Denechaud et al. / FEBS Letters 582 (2008) 68–73eﬀects secondary to lowering plasma insulin and glucose
levels [55].4. Conclusion and perspectives
Clearly, a deﬁciency in ChREBP ameliorates the phenotype
of ob/ob mice and suggests that an inhibition of ChREBP
could be a beneﬁt for the treatment of hepatic steatosis and
other related diseases (Fig. 4). However the limitation of our
studies is the use of ob/ob mice and a model of diet-induced
obesity in C57BL/6J mice would be necessary to address the
role of ChREBP in hepatic steatosis in the context of normal
leptin signaling. Nevertheless, ChREBP appears as a potential
therapeutic target and therefore an accurate knowledge of the
mechanisms involved in regulating its expression and activa-
tion is crucial for the development of pharmacological ap-
proaches for the treatment of metabolic diseases. The
mechanism responsible for ChREBP activation is thought to
involve the dephosphorylation of Serine residue 196 (Ser-
196), a target of protein kinase A (PKA), localized near the nu-
clear localization signal. At low glucose concentrations ChRE-
BP is an inactive phosphorylated cytosolic protein while at
high glucose concentrations, ChREBP undergoes dephospho-
rylation (on Ser-196), and is translocated into the nucleus to
activate its target genes. Since it was not clearly demonstrated
on the endogenous protein, the regulation of ChREBP by
phosphorylation/dephosphorylation remains controversial
[56,57]. Future studies should help in the future to clarify the
mechanisms involved in regulating ChREBP expression, nu-
cleo-cytoplasmic shuttling and its post-traductional modiﬁca-
tions. These studies will be helpful for the development of
potential therapeutic approaches for the treatment of diseases
characterized by dysregulations of glucose and/or lipid metab-
olism.
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